![Kerry Russell](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profilo
Kerry Russell worked as Vice President-Clinical Development at Dicerna Pharmaceuticals, Inc. from 2020 to 2022.
Dr. Russell also held the same position at resTORbio, Inc. Dr. Russell then became the Chief Medical Officer-Metabolic at Terns Pharmaceuticals, Inc. in 2023.
Dr. Russell completed an undergraduate degree at Rice University and obtained doctorate degrees from The University of Texas at Austin and The University of Texas Health Science Center at Houston.
Precedenti posizioni note di Kerry Russell
Società | Posizione | Fine |
---|---|---|
TERNS PHARMACEUTICALS, INC. | Direttore Tecnico/Scientifico/R&S | 01/05/2023 |
DICERNA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/05/2022 |
DICERNA PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
ADICET BIO, INC. | Corporate Officer/Principal | - |
Formazione di Kerry Russell
Rice University | Undergraduate Degree |
The University of Texas at Austin | Doctorate Degree |
The University of Texas Health Science Center at Houston | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
TERNS PHARMACEUTICALS, INC. | Health Technology |
Aziende private | 2 |
---|---|
resTORbio, Inc.
![]() resTORbio, Inc. BiotechnologyHealth Technology resTORbio, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the development and commercialization of medicines for aging-related diseases and conditions. It offers an immunotherapy under the TORC1 program. The company was founded by Chen Schor and Joan Mannick on July 5, 2016 and is headquartered in Boston, MA. | Health Technology |
Dicerna Pharmaceuticals, Inc.
![]() Dicerna Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson, and John J. Rossi in October 2006 and is headquartered in Lexington, MA. | Health Technology |
- Borsa valori
- Insiders
- Kerry Russell